AgeX Therapeutics is focused on the development and commercialization of novel therapeutics targeting human aging. Building on a foundation of proprietary technologies such as PureStem® and induced Tissue Regeneration (iTR™) to develop innovative medicines designed to address some of the largest unsolved problems in aging. PureStem® technology ability to generate pluripotent stem cell-derived young cells of any type for potential application in a range of degenerative diseases of aging with a high unmet medical need. iTR™ is our revolutionary longevity platform aiming to unlock cellular immortality and regenerative capacity to reverse age-related changes in the body. AgeX’s lead product utilizing PureStem® technology is AGEX-VASC1, which is a cell-based therapy in the preclinical stage of development comprised of vascular endothelial progenitor cells for cardiac ischemia as a lead indication. Dr. Michael West is the CEO and Founder of AgeX Therapeutics. AgeX Therapeutic’s lead iTR™ drug-based therapeutic candidate in development is AGEX-iTR1547: AGEX-iTR1547 is a drug-based formulation in preclinical development intended to restore regenerative potential in a wide array of aged tissues afflicted with degenerative disease using our proprietary iTR™ technology. CEO and founder Dr. Michael West.